Nanomaterials (Sep 2021)

Carbon Dioxide-Derived Biodegradable and Cationic Polycarbonates as a New siRNA Carrier for Gene Therapy in Pancreatic Cancer

  • Xinmeng Zhang,
  • Zheng-Ian Lin,
  • Jingyu Yang,
  • Guan-Lin Liu,
  • Zulu Hu,
  • Haoqiang Huang,
  • Xiang Li,
  • Qiqi Liu,
  • Mingze Ma,
  • Zhourui Xu,
  • Gaixia Xu,
  • Ken-Tye Yong,
  • Wei-Chung Tsai,
  • Tzu-Hsien Tsai,
  • Bao-Tsan Ko,
  • Chih-Kuang Chen,
  • Chengbin Yang

DOI
https://doi.org/10.3390/nano11092312
Journal volume & issue
Vol. 11, no. 9
p. 2312

Abstract

Read online

Pancreatic cancer is an aggressive malignancy associated with poor prognosis and a high tendency in developing infiltration and metastasis. K-ras mutation is a major genetic disorder in pancreatic cancer patient. RNAi-based therapies can be employed for combating pancreatic cancer by silencing K-ras gene expression. However, the clinical application of RNAi technology is appreciably limited by the lack of a proper siRNA delivery system. To tackle this hurdle, cationic poly (cyclohexene carbonate) s (CPCHCs) using widely sourced CO2 as the monomer are subtly synthesized via ring-opening copolymerization (ROCOP) and thiol-ene functionalization. The developed CPCHCs could effectively encapsulate therapeutic siRNA to form CPCHC/siRNA nanoplexes (NPs). Serving as a siRNA carrier, CPCHC possesses biodegradability, negligible cytotoxicity, and high transfection efficiency. In vitro study shows that CPCHCs are capable of effectively protecting siRNA from being degraded by RNase and promoting a sustained endosomal escape of siRNA. After treatment with CPCHC/siRNA NPs, the K-ras gene expression in both pancreatic cancer cell line (PANC-1 and MiaPaCa-2) are significantly down-regulated. Subsequently, the cell growth and migration are considerably inhibited, and the treated cells are induced into cell apoptotic program. These results demonstrate the promising potential of CPCHC-mediated siRNA therapies in pancreatic cancer treatment.

Keywords